Christian Georg Stief
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Georg Stief has a total of 952 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Buchner
Department of Urology, University Hospital, LMU Munich, Munich, Germany
37 shared publications - Gerald Bastian Schulz
Department of Urology, LMU University Hospital, Marchioninistraße 15, 81377 Munich, Germany
27 shared publications - Nikolaos Pyrgidis
Department of Urology, University Hospital of the LMU Munich, 81377 Munich, Germany
22 shared publications - Frank Strittmatter
Klinikum der Universität München-Großhadern
21 shared publications - Martin Hennenberg
Department of Urology LMU University Hospital, LMU Munich Munich Germany
21 shared publications C. Gratzke
Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 81377, München, Deutschland
20 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in Clinical Genitourinary Cancer
Impact of Preoperative Sarcopenia on Survival and Perioperative Outcomes After Radical Cystectomy for Bladder Cancer
- 13 October 2026
- Published by Elsevier in Clinical Genitourinary Cancer
Open AccessImpact of Preoperative Sarcopenia on Survival and Perioperative Outcomes After Radical Cystectomy for Bladder Cancer
- Open Access
- 26 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7486
Does Timing Matter? Perioperative Outcomes and Quality of Life After Early Versus Delayed Radical Cystectomy Following BCG Therapy
Objectives: To determine whether the timing of radical cystectomy (RC), either early versus delayed following BCG therapy, affects perioperative outcomes and health-related quality of life (HRQOL) in patients with very-high-risk non–muscle invasive bladder cancer (NMIBC). While existing data focus on oncological endpoints, the impact of BCG on these outcomes remains unevaluated. Methods: We retrospectively analysed a prospectively maintained database of 126 patients undergoing RC for very-high-risk NMIBC at a tertiary referral centre, stratified into early RC (n = 81) and delayed RC (n = 45, following BCG therapy). Perioperative outcomes, HRQOL assessed by EORTC-QLQ-C30 at baseline and 3, 12, and 24 months postoperative, and overall survival (OS) were compared. Longitudinal HRQOL changes were analysed using linear mixed-effects models adjusted for age and Carcinoma in situ (CIS) status, correcting for multiple comparisons. Results: Groups were well-balanced at baseline regarding age, sex, BMI, and ECOG performance status. No significant between-group differences were observed in overall complication rates, hospital stay length, or any QLQ-C30 domain at any timepoint, including global health status (GHS), in linear mixed-effects models accounting for repeated measures and multiple comparisons. OS did not differ between groups (p = 0.720). Conclusions: Prior BCG therapy does not adversely influence perioperative outcomes or HRQOL following RC for very-high-risk NMIBC. These findings support the initial use of BCG in eligible patients, as a trial of intravesical therapy does not appear to compromise surgical safety or postoperative quality of life when cystectomy is ultimately required.
- 26 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7486
Open AccessDoes Timing Matter? Perioperative Outcomes and Quality of Life After Early Versus Delayed Radical Cystectomy Following BCG Therapy
Objectives: To determine whether the timing of radical cystectomy (RC), either early versus delayed following BCG therapy, affects perioperative outcomes and health-related quality of life (HRQOL) in patients with very-high-risk non–muscle invasive bladder cancer (NMIBC). While existing data focus on oncological endpoints, the impact of BCG on these outcomes remains unevaluated. Methods: We retrospectively analysed a prospectively maintained database of 126 patients undergoing RC for very-high-risk NMIBC at a tertiary referral centre, stratified into early RC (n = 81) and delayed RC (n = 45, following BCG therapy). Perioperative outcomes, HRQOL assessed by EORTC-QLQ-C30 at baseline and 3, 12, and 24 months postoperative, and overall survival (OS) were compared. Longitudinal HRQOL changes were analysed using linear mixed-effects models adjusted for age and Carcinoma in situ (CIS) status, correcting for multiple comparisons. Results: Groups were well-balanced at baseline regarding age, sex, BMI, and ECOG performance status. No significant between-group differences were observed in overall complication rates, hospital stay length, or any QLQ-C30 domain at any timepoint, including global health status (GHS), in linear mixed-effects models accounting for repeated measures and multiple comparisons. OS did not differ between groups (p = 0.720). Conclusions: Prior BCG therapy does not adversely influence perioperative outcomes or HRQOL following RC for very-high-risk NMIBC. These findings support the initial use of BCG in eligible patients, as a trial of intravesical therapy does not appear to compromise surgical safety or postoperative quality of life when cystectomy is ultimately required.
- Open Access
Sizing up Testicular Masses: Clinical Implications of Lesion Size and Contralateral Biopsy
Background/Objectives: Accurate preoperative discrimination between benign and malignant testicular masses remains challenging. Lesion size has been suggested as a predictor, but robust cutoffs and the role of contralateral biopsy remain uncertain. Methods: We retrospectively analyzed a prospectively maintained single-center database of 387 patients treated for testicular lesions between December 2013 and November 2024. Patients with malignant non-germ cell histologies or prior systemic GCT therapy were excluded. Lesion size was evaluated as a predictor of malignancy using ROC analysis, logistic regression, and predefined cutoffs (5, 8, 10, 15 mm). Associations between contralateral biopsy results and clinical variables were assessed using uni- and multivariable analyses. Results: Of 387 patients, 284 (73.4%) had malignant GCTs. Malignant lesions were significantly larger than benign ones (median 25.0 vs. 5.5 mm, p < 0.001). Lesion size showed good discrimination between benign and malignant lesions (AUC 0.829, 95% CI 0.784–0.874), with a Youden-derived optimal cutoff of 12.5 mm. Internal bootstrap validation (2000 resamples) yielded a median optimal cutoff of 12.5 mm (95% percentile interval 7.45–19.5 mm), indicating uncertainty regarding the exact threshold. Among 360 patients with complete clinical and tumor-marker data, combining lesion size with age, AFP, β-HCG, and LDH significantly improved discrimination compared with lesion size alone (AUC 0.863 vs. 0.818; DeLong p = 0.003). Contralateral biopsy was performed in 249 patients, with 7 (2.8%) positive for GCNIS. Younger age was associated with contralateral GCNIS, while tumor size, serum markers, and histology were not predictive. Multivariable analysis showed no significant predictors. Conclusions: Lesion size is a strong predictor of malignant histology, although the optimal size threshold remains subject to uncertainty. Combining lesion size with readily available clinical and biochemical parameters may further improve preoperative risk stratification. Contralateral GCNIS was rare and not reliably predicted, supporting individualized biopsy strategies.
Open AccessSizing up Testicular Masses: Clinical Implications of Lesion Size and Contralateral Biopsy
Background/Objectives: Accurate preoperative discrimination between benign and malignant testicular masses remains challenging. Lesion size has been suggested as a predictor, but robust cutoffs and the role of contralateral biopsy remain uncertain. Methods: We retrospectively analyzed a prospectively maintained single-center database of 387 patients treated for testicular lesions between December 2013 and November 2024. Patients with malignant non-germ cell histologies or prior systemic GCT therapy were excluded. Lesion size was evaluated as a predictor of malignancy using ROC analysis, logistic regression, and predefined cutoffs (5, 8, 10, 15 mm). Associations between contralateral biopsy results and clinical variables were assessed using uni- and multivariable analyses. Results: Of 387 patients, 284 (73.4%) had malignant GCTs. Malignant lesions were significantly larger than benign ones (median 25.0 vs. 5.5 mm, p < 0.001). Lesion size showed good discrimination between benign and malignant lesions (AUC 0.829, 95% CI 0.784–0.874), with a Youden-derived optimal cutoff of 12.5 mm. Internal bootstrap validation (2000 resamples) yielded a median optimal cutoff of 12.5 mm (95% percentile interval 7.45–19.5 mm), indicating uncertainty regarding the exact threshold. Among 360 patients with complete clinical and tumor-marker data, combining lesion size with age, AFP, β-HCG, and LDH significantly improved discrimination compared with lesion size alone (AUC 0.863 vs. 0.818; DeLong p = 0.003). Contralateral biopsy was performed in 249 patients, with 7 (2.8%) positive for GCNIS. Younger age was associated with contralateral GCNIS, while tumor size, serum markers, and histology were not predictive. Multivariable analysis showed no significant predictors. Conclusions: Lesion size is a strong predictor of malignant histology, although the optimal size threshold remains subject to uncertainty. Combining lesion size with readily available clinical and biochemical parameters may further improve preoperative risk stratification. Contralateral GCNIS was rare and not reliably predicted, supporting individualized biopsy strategies.
- Open Access
- 10 July 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 245, 116945
Plasma infrared molecular fingerprinting for prostate cancer detection: prospective evidence for a partially PSA-independent signal
- 10 July 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 245, 116945
Open AccessPlasma infrared molecular fingerprinting for prostate cancer detection: prospective evidence for a partially PSA-independent signal
- Open Access
- 20 June 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (6) , 102604
Baseline Sarcopenia is Associated With Overall Survival but Not Toxicity in Patients Receiving Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
- 20 June 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (6) , 102604
Open AccessBaseline Sarcopenia is Associated With Overall Survival but Not Toxicity in Patients Receiving Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
- Open Access
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Plasma infrared molecular fingerprinting for prostate cancer detection: prospective evidence for a partially PSA-independent signal
Background: Prostate-specific antigen (PSA) testing has limited specificity, particularly at intermediate PSA concentrations, contributing to diagnostic uncertainty in prostate cancer (PCa). Infrared molecular fingerprinting (IMF) provides rapid plasma-based readout of disease-associated biochemical alterations, and may capture molecular information that is not fully reflected by PSA concentration.Methods: In the prospective Lasers4Life study, plasma from 2,024 men was analysed, including 1,012 treatment-naïve PCa patients, 752 men with benign prostatic hyperplasia (BPH), and 260 asymptomatic controls. Classification models were evaluated using cross-validation and, for PCa-vs-BPH discrimination, temporally independent held-out cohort testing. Diagnostic performance was quantified by the area under the receiver operating characteristic curve (ROC AUC) and examined across PSA strata, comorbidities and medications.Results: IMF discriminated PCa from asymptomatic controls (AUC 0.79 ± 0.08) and from BPH (AUC 0.67 ± 0.04) in cross-validation. In an exploratory age- and PSA-matched subset of individuals with PSA below 12 ng/mL (comprising 200 PCa and 200 BPH cases), IMF showed higher discrimination than PSA alone (AUC 0.63 vs 0.56; p < 1×10⁻⁴). Most examined comorbidities and medications did not strongly alter IMF performance, except prostatitis modestly reduced discrimination.Conclusions: IMF detected PCa-associated molecular signatures in plasma, including signals partly independent of PSA. However, diagnostic discrimination was modest, and clinical utility remains to be proven. Independent validation, clinically significant PCa endpoints, and demonstration of additive value within established diagnostic pathways are required.
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPlasma infrared molecular fingerprinting for prostate cancer detection: prospective evidence for a partially PSA-independent signal
Background: Prostate-specific antigen (PSA) testing has limited specificity, particularly at intermediate PSA concentrations, contributing to diagnostic uncertainty in prostate cancer (PCa). Infrared molecular fingerprinting (IMF) provides rapid plasma-based readout of disease-associated biochemical alterations, and may capture molecular information that is not fully reflected by PSA concentration.Methods: In the prospective Lasers4Life study, plasma from 2,024 men was analysed, including 1,012 treatment-naïve PCa patients, 752 men with benign prostatic hyperplasia (BPH), and 260 asymptomatic controls. Classification models were evaluated using cross-validation and, for PCa-vs-BPH discrimination, temporally independent held-out cohort testing. Diagnostic performance was quantified by the area under the receiver operating characteristic curve (ROC AUC) and examined across PSA strata, comorbidities and medications.Results: IMF discriminated PCa from asymptomatic controls (AUC 0.79 ± 0.08) and from BPH (AUC 0.67 ± 0.04) in cross-validation. In an exploratory age- and PSA-matched subset of individuals with PSA below 12 ng/mL (comprising 200 PCa and 200 BPH cases), IMF showed higher discrimination than PSA alone (AUC 0.63 vs 0.56; p < 1×10⁻⁴). Most examined comorbidities and medications did not strongly alter IMF performance, except prostatitis modestly reduced discrimination.Conclusions: IMF detected PCa-associated molecular signatures in plasma, including signals partly independent of PSA. However, diagnostic discrimination was modest, and clinical utility remains to be proven. Independent validation, clinically significant PCa endpoints, and demonstration of additive value within established diagnostic pathways are required.
- Open Access
- 26 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2536
Trends in Treatment and Perioperative Outcomes of Upper Tract Urothelial Carcinoma: The Evolving Role of Lymphadenectomy and Neoadjuvant Chemotherapy
Objectives: Real-world data on surgical and multimodal management of upper tract urothelial carcinoma (UTUC) are limited. This study examined epidemiological trends, nephron-sparing surgery adoption, and the perioperative impact of lymphadenectomy (LND) and neoadjuvant chemotherapy (NAC). Methods: The German Nationwide Inpatient Data (GRAND) registry (2005–2023) identified UTUC patients undergoing radical nephroureterectomy (RNU), endoscopic laser destruction, or segmental ureteral resection (SUR) using OPS codes. Demographics, comorbidities, complications, and in-hospital mortality were extracted from ICD-10-GM data. Multivariable regression adjusted for baseline comorbidities assessed associations between treatment type, LND, NAC, and perioperative outcomes. Results: Among 53,427 UTUC patients, 77.3% underwent RNU, 13.8% endoscopic laser destruction, and 8.9% SUR. Endoscopic laser use rose from <10% (2005) to about 20% (2023). LND was performed in 13% of RNU cases, increasing from 1.1% to 19%. LND was associated with higher risks of transfusion (OR 1.47, 95% CI 1.37–1.57), acute kidney injury (OR 1.19, 95% CI 1.07–1.32), and ICU admission (OR 1.21, 95% CI 1.13–1.30), without affecting in-hospital mortality. NAC was given to 1.7% of patients, with a five-fold increase over time, and was associated with more transfusions (OR 1.28, 95% CI 1.07–1.52) and urinomas (OR 2.31, 95% CI 1.31–3.78), but not mortality. Conclusions: UTUC management is evolving, with growing use of endoscopic laser therapy and guideline-aligned lymphadenectomy during nephroureterectomy. Neoadjuvant chemotherapy remains underused despite acceptable perioperative safety, highlighting the need for increased awareness to optimize multimodal treatment.
- 26 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2536
Open AccessTrends in Treatment and Perioperative Outcomes of Upper Tract Urothelial Carcinoma: The Evolving Role of Lymphadenectomy and Neoadjuvant Chemotherapy
Objectives: Real-world data on surgical and multimodal management of upper tract urothelial carcinoma (UTUC) are limited. This study examined epidemiological trends, nephron-sparing surgery adoption, and the perioperative impact of lymphadenectomy (LND) and neoadjuvant chemotherapy (NAC). Methods: The German Nationwide Inpatient Data (GRAND) registry (2005–2023) identified UTUC patients undergoing radical nephroureterectomy (RNU), endoscopic laser destruction, or segmental ureteral resection (SUR) using OPS codes. Demographics, comorbidities, complications, and in-hospital mortality were extracted from ICD-10-GM data. Multivariable regression adjusted for baseline comorbidities assessed associations between treatment type, LND, NAC, and perioperative outcomes. Results: Among 53,427 UTUC patients, 77.3% underwent RNU, 13.8% endoscopic laser destruction, and 8.9% SUR. Endoscopic laser use rose from <10% (2005) to about 20% (2023). LND was performed in 13% of RNU cases, increasing from 1.1% to 19%. LND was associated with higher risks of transfusion (OR 1.47, 95% CI 1.37–1.57), acute kidney injury (OR 1.19, 95% CI 1.07–1.32), and ICU admission (OR 1.21, 95% CI 1.13–1.30), without affecting in-hospital mortality. NAC was given to 1.7% of patients, with a five-fold increase over time, and was associated with more transfusions (OR 1.28, 95% CI 1.07–1.52) and urinomas (OR 2.31, 95% CI 1.31–3.78), but not mortality. Conclusions: UTUC management is evolving, with growing use of endoscopic laser therapy and guideline-aligned lymphadenectomy during nephroureterectomy. Neoadjuvant chemotherapy remains underused despite acceptable perioperative safety, highlighting the need for increased awareness to optimize multimodal treatment.
- 19 January 2026
- Published by S. Karger AG in Urologia Internationalis
- p. 1-10
Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study
Introduction: Androgen deprivation therapy (ADT) plus 6 cycles of docetaxel was the global first-line standard for metastatic hormone-sensitive prostate cancer (mHSPC) before triplet regimens emerged. In many regions, this approach remains the only accessible option. Whether extending docetaxel beyond six cycles provides additional benefit remains uncertain. This study evaluated the efficacy and safety of extended docetaxel in newly diagnosed mHSPC. Methods: We conducted a retrospective cohort study of 98 mHSPC patients treated with ADT plus docetaxel (75 mg/m2) at a German tertiary center (2014–2022). Patients were grouped by treatment duration: 4–6 cycles (n = 60) vs. 7–10 cycles (n = 38). Progression-free survival (PFS1), time to progression after subsequent therapy, and overall survival (OS) were analyzed using Kaplan-Meier and Cox models. Adverse events were graded per CTCAE v5.0. Results: Median PFS1 was similar between groups (12.6 vs. 12.2 months; HR 1.13; p = 0.713), as was OS (38.5 vs. 52.9 months; HR 0.99; p = 0.958). Extended treatment led to higher overall toxicity (68.4% vs. 38.3%; p = 0.004), mainly peripheral neuropathy and dermatologic events, while severe events (grade ≥3) were comparable (7.9% vs. 8.3%). Conclusion: Extending docetaxel beyond six cycles in first-line mHSPC offers no survival advantage and increases toxicity. Six cycles remain an effective, pragmatic standard where triplet therapy is unavailable.
- 19 January 2026
- Published by S. Karger AG in Urologia Internationalis
- p. 1-10
Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study
Introduction: Androgen deprivation therapy (ADT) plus 6 cycles of docetaxel was the global first-line standard for metastatic hormone-sensitive prostate cancer (mHSPC) before triplet regimens emerged. In many regions, this approach remains the only accessible option. Whether extending docetaxel beyond six cycles provides additional benefit remains uncertain. This study evaluated the efficacy and safety of extended docetaxel in newly diagnosed mHSPC. Methods: We conducted a retrospective cohort study of 98 mHSPC patients treated with ADT plus docetaxel (75 mg/m2) at a German tertiary center (2014–2022). Patients were grouped by treatment duration: 4–6 cycles (n = 60) vs. 7–10 cycles (n = 38). Progression-free survival (PFS1), time to progression after subsequent therapy, and overall survival (OS) were analyzed using Kaplan-Meier and Cox models. Adverse events were graded per CTCAE v5.0. Results: Median PFS1 was similar between groups (12.6 vs. 12.2 months; HR 1.13; p = 0.713), as was OS (38.5 vs. 52.9 months; HR 0.99; p = 0.958). Extended treatment led to higher overall toxicity (68.4% vs. 38.3%; p = 0.004), mainly peripheral neuropathy and dermatologic events, while severe events (grade ≥3) were comparable (7.9% vs. 8.3%). Conclusion: Extending docetaxel beyond six cycles in first-line mHSPC offers no survival advantage and increases toxicity. Six cycles remain an effective, pragmatic standard where triplet therapy is unavailable.
- Open Access
- 14 January 2026
- Published by Springer Nature in Die Onkologie
- Vol. 32 (1) , 2-4
Blasenkarzinom und ableitende Harnwege
- 14 January 2026
- Published by Springer Nature in Die Onkologie
- Vol. 32 (1) , 2-4
Open AccessBlasenkarzinom und ableitende Harnwege
- Open Access
- 6 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1864
Pine-Extracted Phytosterol β-Sitosterol (APOPROSTAT® Forte) Inhibits Both Human Prostate Smooth Muscle Contraction and Prostate Stromal Cell Growth, Without Cytotoxic Effects: A Mechanistic Link to Clinical Efficacy in LUTS/BPH
Introduction: Medical treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) targets prostate smooth muscle tone for rapid relieve of symptoms and prostate size to prevent disease progression. Recently, EAU guidelines introduced phytomedicines for treatment of LUTS/BPH. Phytosterols may reduce the risk of prostate diseases and seem to be the smallest common denominator between different phytotherapeutic preparations. Thus, we investigated the effects of the highly concentrated phytosterol β-sitosterol on human prostate smooth muscle contraction and cellular functions, including contraction and growth of prostate stromal cells. Materials and Methods: APOPROSTAT® forte capsules (>70% β-sitosterol, ethanol extract of Pinus pinaster) were dissolved in ethanol. Contractions were induced in human prostate tissues (n = 100) obtained from radical prostatectomy and assessed in organ bath setups. Cytoskeletal organization, proliferation, viability, cytotoxicity, and contraction in stromal cells (WPMY-1) were assessed using phalloidin staining, EdU, colony formation, CCK-8, flow cytometry, and matrix collagen assays. Results: APOPROSTAT® forte (0.1–30 µg/mL) inhibited adrenergic, non-adrenergic, and neurogenic contractions of human prostate tissues by up to 71%, 69%, and 63%, respectively, in a dose-dependent manner. In WPMY-1 cells, it reduced proliferation and actin organization by up to 67% and 75% after 72 h, without affecting viability or inducing cytotoxicity. Colony formation decreased by up to 60% after 168 h, and contraction in collagen matrix assays was reduced by 57% in a concentration- and time-dependent manner. Conclusions: The natural phytosterol β-sitosterol effectively inhibits both prostate contraction and growth with a favorable safety profile, supporting its beneficial role in LUTS management through phytotherapy.
- 6 December 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1864
Open AccessPine-Extracted Phytosterol β-Sitosterol (APOPROSTAT® Forte) Inhibits Both Human Prostate Smooth Muscle Contraction and Prostate Stromal Cell Growth, Without Cytotoxic Effects: A Mechanistic Link to Clinical Efficacy in LUTS/BPH
Introduction: Medical treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) targets prostate smooth muscle tone for rapid relieve of symptoms and prostate size to prevent disease progression. Recently, EAU guidelines introduced phytomedicines for treatment of LUTS/BPH. Phytosterols may reduce the risk of prostate diseases and seem to be the smallest common denominator between different phytotherapeutic preparations. Thus, we investigated the effects of the highly concentrated phytosterol β-sitosterol on human prostate smooth muscle contraction and cellular functions, including contraction and growth of prostate stromal cells. Materials and Methods: APOPROSTAT® forte capsules (>70% β-sitosterol, ethanol extract of Pinus pinaster) were dissolved in ethanol. Contractions were induced in human prostate tissues (n = 100) obtained from radical prostatectomy and assessed in organ bath setups. Cytoskeletal organization, proliferation, viability, cytotoxicity, and contraction in stromal cells (WPMY-1) were assessed using phalloidin staining, EdU, colony formation, CCK-8, flow cytometry, and matrix collagen assays. Results: APOPROSTAT® forte (0.1–30 µg/mL) inhibited adrenergic, non-adrenergic, and neurogenic contractions of human prostate tissues by up to 71%, 69%, and 63%, respectively, in a dose-dependent manner. In WPMY-1 cells, it reduced proliferation and actin organization by up to 67% and 75% after 72 h, without affecting viability or inducing cytotoxicity. Colony formation decreased by up to 60% after 168 h, and contraction in collagen matrix assays was reduced by 57% in a concentration- and time-dependent manner. Conclusions: The natural phytosterol β-sitosterol effectively inhibits both prostate contraction and growth with a favorable safety profile, supporting its beneficial role in LUTS management through phytotherapy.